CSF2 and neoplasm: To prepare potent therapeutic autologous cDC1-based immunotherapy capable of eliciting strong anti-tumor responses, patients undergo apheresis followed by differentiation of the monocyte fraction into DCs using GM-CSF and IL-4 [48].